List of Contents

Asthma Drugs Market Size, Share, and Trends 2024 to 2034

Asthma Drugs Market (By Medication: Quick Relief Medications, Long-term Control Medications, Others; By Mode of Administration: Tablets and Capsules, Liquids, Inhalers, Injections, and Sprays and Powders; By Organization Type: Public, Private; By Application: Pediatric, Adults, Adolescent) - Global Market Size, Share, Growth, Trends Analysis, Regional Outlook and Forecasts 2024 - 2033

  • Last Updated : February 2024
  • Report Code : 1225
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Asthma Drugs Market Market 

5.1. COVID-19 Landscape: Asthma Drugs Market Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Asthma Drugs Market Market, By Medication

8.1. Asthma Drugs Market Market Revenue and Volume Forecast, by Medication, 2024-2033

8.1.1. Quick Relief Medications

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Long-term Control Medications

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Others

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Asthma Drugs Market Market, By Mode of Administration

9.1. Asthma Drugs Market Market Revenue and Volume Forecast, by Mode of Administration, 2024-2033

9.1.1. Tablets and Capsules

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Liquids

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Inhalers

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. Injections

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Asthma Drugs Market Market, By Organization Type 

10.1. Asthma Drugs Market Market Revenue and Volume Forecast, by Organization Type, 2024-2033

10.1.1. Public

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Private

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Asthma Drugs Market Market, By Application 

11.1. Asthma Drugs Market Market Revenue and Volume Forecast, by Application, 2024-2033

11.1.1. Pediatric

11.1.1.1. Market Revenue and Volume Forecast (2021-2033)

11.1.2. Adults

11.1.2.1. Market Revenue and Volume Forecast (2021-2033)

11.1.3. Adolescent

11.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 12. Global Asthma Drugs Market Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.1.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.1.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.1.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.1.5.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.1.5.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.1.5.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.1.6.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.1.6.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.1.6.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.2.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.2.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.2.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.2.5.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.2.5.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.2.5.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.2.6.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.2.6.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.2.6.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.2.7.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.2.7.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.2.7.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.2.8.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.2.8.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.2.8.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.3.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.3.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.3.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.3.5.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.3.5.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.3.5.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.3.6.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.3.6.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.3.6.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.3.7.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.3.7.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.3.7.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.3.8.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.3.8.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.3.8.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.4.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.4.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.4.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.4.5.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.4.5.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.4.5.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.4.6.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.4.6.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.4.6.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.4.7.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.4.7.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.4.7.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.4.8.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.4.8.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.4.8.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.5.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.5.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.5.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.5.5.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.5.5.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.5.5.4. Market Revenue and Volume Forecast, by Application (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Medication (2021-2033)

12.5.6.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)

12.5.6.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)

12.5.6.4. Market Revenue and Volume Forecast, by Application (2021-2033)

Chapter 13. Company Profiles

13.1. GlaxoSmithKline

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Pfizer

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Vectura Group

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Boehringer Ingelheim

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Roche

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Novartis

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Merck

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. AstraZeneca

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Teva Pharmaceutical

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

 

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The asthma drugs market size was reached at USD 23.93 billion in 2023 and is predicted to hit over USD 39.35 billion by 2033.

The global asthma drugs market is growing at a CAGR of 5.09% during the forecast period 2024 to 2033.

Increasing prevalence of asthma and growth in the old age population are driving factors for the growth of asthma market. Ongoing R&D activities and technological advancements can create lucrative growth opportunities for the key players operating in the global asthma drugs market. High costs associated with the research and development of the asthma drugs is key factor hampering growth of the global market.

North America will dominate the global industry due to huge investments in healthcare sector and growing research and development activities in the countries is predictable create tremendous demand for the asthma drugs, in the countries of the North America.

Asia Pacific is likely to list the noteworthy CAGR, on account of increased initiatives by the government in order to creates awareness regarding health in emerging economies.

The major companies functioning in the worldwide GlaxoSmithKline, Pfizer, Vectura Group, Boehringer Ingelheim, Roche, Novartis, Merck, AstraZeneca, Teva Pharmaceutical among others.

Long-term control medications segment is expected to hold the prime revenue share by medication type due to increasing need for the long-term control medications in order to treat chronic diseases that are considered as asthma.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us